Pyoderma Gangrenosum: Treatment Options.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limite...
| Publicado en: | Drugs Vol. 83; no. 14; pp. 1255 - 1268 |
|---|---|
| Autores principales: | , , , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
Springer Nature
Sep2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=172040500&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 172040500 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00126667 C5A jtl: Drugs issn: 00126667 maglogo: N pubinfo: dt: Sep2023 vid: 83 iid: 14 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 172040500 170075722 172040500 172040500 10.1007/s40265-023-01931-3 172040500 ppf: 1255 ppct: 13 formats: tig: atl: Pyoderma Gangrenosum: Treatment Options. aug: au: Dissemond, Joachim Marzano, Angelo V. Hampton, Philip J. Ortega-Loayza, Alex G. affil: Department of Dermatology, Venerology and Allergology, University of Essen, Hufelandstr. 55, 45147, Essen, Germany sug: subj: Pyoderma Gangrenosum Therapy Rare Diseases Therapy Early Intervention Methods Tumor Necrosis Factor Antagonists and Inhibitors Interleukins Antagonists and Inhibitors Biological Products Chemistry, Pharmaceutical Methods ab: Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|